Changchun High-tech: Jin Sai Pharmaceutical pays 32.7 million euros to obtain exclusive rights to three ALK products in mainland China.

Changchun Hi-tech announced that its holding subsidiary Jinsai Pharmaceutical has reached a cooperation agreement with Denmark's ALK-Abell A/S company on the development and commercialization of ALK's house dust mite allergen-specific immunotherapy products in China, and has obtained the exclusive agency rights for three products developed independently by ALK in mainland China. According to the agreement, Jinsai Pharmaceutical will pay an initial payment of 32.7 million euros. For the clinical trial approval progress of sublingual tablets for dust mite allergen adults, adolescents, and children in the Chinese region, Jinsai Pharmaceutical will pay a milestone payment of 40 million euros. In the future, depending on the sales of the above products in the Chinese market, Jinsai Pharmaceutical may make additional milestone payments of up to 105 million euros.